24 juli, 2026
The ‘Slow-SPEED’ trials are the first non-pharmacological Parkinson’s disease prevention trials worldwide, targeting isolated REM-sleep behaviour disorder (iRBD) as a Parkinson’s disease at-risk group. Three trials examine the feasibility and preliminary efficacy of a gamified, remotely administered exercise intervention vs. active control over 18–36 months in complementary prodromal subgroups: iRBD(n = 110; Netherlands), hyposmia(n = 110; United Kingdom) or LRRK2/GBA1 mutation carriers(n = 600; United States). These trials will provide unique insights for large-scale Parkinson’s prevention studies.
Read the full protocol: Slow-SPEED: protocol for three randomised trials of remotely delivered exercise to prevent Parkinson’s disease”